Bicycle Day 2020 Was Truly Historic, But Not for the Reasons You Think
Jamon A. Rahn, CEO of psychedelic pharmaceutical startup MindMed, offered a glimpse of the future of psychedelic science, including proprietary data and hints of an “LSD neutralizer.”
Eleusis Benefit Corp: Taking the “Psychedelic” Out of Psychedelics
Using psychedelic compounds to treat inflammation is interesting, but claiming that, "the primary traditional use," of psychedelics was, "as imperceptible anti-inflammatory agents," just isn’t true.
BBC Duped into Promoting Marketing Scheme for Microdosing Psychedelics
A recent BBC story entitled “The ‘psychedelics coach’ with drug-fuelled career advice,” offers an opportunity to examine what happens when sloppy journalism and self-promotional psychedelic marketers collide.
This is what psychedelic mainstreaming looks like…in Arizona
As psychedelic medicalization and the potential profits of a “virgin market” loom large, new organizations are increasingly looking to gain legitimacy within the field. Mainstreaming means the doors of this field are being thrown wide open.
It’s time to debunk prohibitionist narratives and calls for monopolies within psychedelic science
As venture-capital-backed, for-profit companies barrel into psychedelic therapy, the potential for the widespread privatization of psychedelic knowledge and profits looms large. Some researchers are so enthusiastic about medicalization by “any means necessary” that they’re resorting to prohibitionist historical narratives and calling for monopolies to push the agenda forward.
